# A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

> **NCT02012920** · PHASE2 · COMPLETED · sponsor: **Innocrin Pharmaceutical** · enrollment: 200 (estimated)

## Conditions studied

- Castration-resistant Prostate Cancer
- CRPC

## Interventions

- **DRUG:** Seviteronel: given orally once daily in 28 day cycles

## Key facts

- **NCT ID:** NCT02012920
- **Lead sponsor:** Innocrin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2018-12
- **Final completion:** 2019-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02012920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02012920, "A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02012920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*